Literature DB >> 23146467

Transplant glomerulopathy: clinical course and factors relating to graft survival.

V López Jiménez1, L Fuentes, T Jiménez, M León, I Garcia, E Sola, M Cabello, C Gutierrez, D Burgos, P Ruiz, D Hernandez.   

Abstract

INTRODUCTION: Transplant glomerulopathy (TG) is usually associated with a poor prognosis for kidney graft survival. AIM AND METHODS: We analyzed 30 cases of TG diagnosed by kidney biopsy among a retrospective review of 579 biopsies performed between January 2006 and October 2011.
RESULTS: At the time of biopsy, the mean glomerular filtration rate (GFR), estimated by the abbreviated Modification of Diet in Renal Disease was 31 ± 10 mL/min and the proteinuria, 1.9 ± 2 gr/24 hours. Anti-human leukocyte antigen (HLA) antibodies were present in 40% of patients. The histological findings showed severe duplication of the glomerular basement membrane in 80% of patients; and interstitial fibrosis and tubular atrophy (IFTA) and moderate to severe arteriolar hyalinosis in 53% and 56% respectively. Fourteen patients lost their grafts. Graft survival was significantly associated with IFTA (P = .03) and renal function at the time of diagnosis (P = .03).
CONCLUSIONS: TG was associated with a worse prognosis for the graft among kidney transplant patients. It is often associated with the presence of anti-HLA antibodies. Renal function at the time of diagnosis and IFTA were predictive factors for graft survival in these patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23146467     DOI: 10.1016/j.transproceed.2012.09.068

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation.

Authors:  Candice Roufosse; Jan Ulrich Becker; Marion Rabant; Daniel Seron; Maria Irene Bellini; Georg A Böhmig; Klemens Budde; Fritz Diekmann; Denis Glotz; Luuk Hilbrands; Alexandre Loupy; Rainer Oberbauer; Liset Pengel; Stefan Schneeberger; Maarten Naesens
Journal:  Transpl Int       Date:  2022-05-20       Impact factor: 3.842

2.  Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy.

Authors:  Pallavi Patri; Surya V Seshan; Marie Matignon; Dominique Desvaux; John R Lee; Jun Lee; Darshana M Dadhania; David Serur; Philippe Grimbert; Choli Hartono; Thangamani Muthukumar
Journal:  Kidney Int       Date:  2016-02       Impact factor: 10.612

3.  Glomerular C3 Deposition Is an Independent Risk Factor for Allograft Failure in Kidney Transplant Recipients With Transplant Glomerulopathy.

Authors:  Sarah E Panzer; Emily Joachim; Sandesh Parajuli; Weixiong Zhong; Brad C Astor; Arjang Djamali
Journal:  Kidney Int Rep       Date:  2019-02-04

Review 4.  Chronic transplant glomerulopathy: New insights into pathogenesis.

Authors:  Avantee Gokhale; Jorge Chancay; Ron Shapiro; Parmjeet Randhawa; Madhav C Menon
Journal:  Clin Transplant       Date:  2021-02-06       Impact factor: 2.863

Review 5.  The importance of C4d in biopsies of kidney transplant recipients.

Authors:  Rosana Rosa Miranda Corrêa; Juliana Reis Machado; Marcos Vinícius da Silva; Fernanda Rodrigues Helmo; Camila Souza Oliveira Guimarães; Laura Penna Rocha; Ana Carolina Guimarães Faleiros; Marlene Antônia dos Reis
Journal:  Clin Dev Immunol       Date:  2013-07-09

Review 6.  Transplant glomerulopathy: the interaction of HLA antibodies and endothelium.

Authors:  William Hanf; Claudine S Bonder; P Toby H Coates
Journal:  J Immunol Res       Date:  2014-03-09       Impact factor: 4.818

7.  Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection.

Authors:  Gastón J Piñeiro; Erika De Sousa-Amorim; Manel Solé; José Ríos; Miguel Lozano; Frederic Cofán; Pedro Ventura-Aguiar; David Cucchiari; Ignacio Revuelta; Joan Cid; Eduard Palou; Josep M Campistol; Federico Oppenheimer; Jordi Rovira; Fritz Diekmann
Journal:  BMC Nephrol       Date:  2018-10-11       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.